Pulse Biosciences
3957 Point Eden Way
Hayward
CA
94545
United States
Tel: 833-257-3393
Website: https://www.pulsebiosciences.com/
Email: info@pulsebiosciences.com
181 articles about Pulse Biosciences
-
Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting
5/18/2023
Pulse Biosciences, Inc. today announced nsPFA will be featured in three presentations at the upcoming Heart Rhythm 2023 Annual Meeting in New Orleans, LA from May 19-21.
-
Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results
5/11/2023
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced financial results for the first quarter ended March 31, 2023.
-
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
5/10/2023
Pulse Biosciences, Inc. today announced that it intends to deliver an irrevocable notice of redemption, on or about May 15, 2023, to redeem all of the common stock warrants that were issued as part of its June 9, 2022 rights offering which are still outstanding as of June 16, 2023.
-
Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer
5/3/2023
Pulse Biosciences, Inc. today announced the appointment of Gansevoort “Gan” Dunnington, M.D. as its Chief Medical Officer.
-
Pulse Biosciences Announces $65 Million Private Placement
5/1/2023
Pulse Biosciences, Inc. today announced that it has entered into a stock purchase agreement with Robert W. Duggan, an experienced life sciences executive and the Company's Executive Chairman, for the purchase of 10,022,937 shares of the Company's common stock.
-
Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023
4/27/2023
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, announced today it will report financial results for the first quarter of 2023 after market close on Thursday, May 11, 2023.
-
Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results
3/30/2023
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, today announced financial results for the fourth quarter and full year ended December 31, 2022.
-
Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023
3/2/2023
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, announced today it will report financial results for the fourth quarter and full year of 2022 after market close on Thursday, March 30, 2023.
-
Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium
2/2/2023
Pulse Biosciences, Inc. today announced its technology will be highlighted in a poster presentation at the 28th Annual International AF Symposium meeting in Boston February 2–4.
-
Pulse Biosciences Reports Third Quarter 2022 Financial Results
11/10/2022
Pulse Biosciences, Inc. today announced financial results for the third quarter ended September 30, 2022.
-
Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022
10/27/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third quarter of 2022 after market close on Thursday, November 10, 2022.
-
Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions
10/6/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced positive clinical data from an FDA approved Investigational Device Exempt treat and resect study on the use of NPS for low-risk basal cell carcinoma (BCC) lesions.
-
Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia
9/26/2022
Pulse Biosciences, Inc. today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its CellFX System.
-
Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation
9/20/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced a shift in focus to advance its core technology.
-
Pulse Biosciences Reports Second Quarter 2022 Financial Results
8/10/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the second quarter ended June 30, 2022.
-
The FDA has had a busy week, accepting drug applications, approving clinical trials and granting various special designations for Gamida Cell, Cellectis, Scynexis & more.
-
Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System
8/4/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance of expanded energy settings for use with the family of CellFX System treatments tips in dermatology.
-
Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022
7/27/2022
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the second quarter of 2022 after market close on Wednesday, August 10, 2022.
-
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 16, 2022
6/16/2022
Pulse Biosciences, Inc. announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Equity Incentive Plan.
-
Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering
6/9/2022
Pulse Biosciences, Inc., a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ technology, announced the closing of its rights offering and the final results thereof.